ICU sedation, delirium & recovery
Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: Does inflammation play a role?
Authors' conclusion
Dexamethasone PK parameters in ICU COVID patients were substantially different from those from non-ICU non-COVID patients, and inflammation may play an important role in dexamethasone exposure.
Study context
- Population
- Critically ill COVID-19 patients receiving fixed-dose IV dexamethasone (6 mg/day)51 samples
- Participants
- 18 patients
- Outcome
- Dexamethasone population PK parameters and relevant covariates
Methodological detailsretrospective, pilot study, NONMEM modelling
- Retrospective
- Pilot study
- NONMEM modelling
Main finding
As reported in the abstract
Population PK estimates (two-compartment model)
Clearance (mean population estimate; inter-individual variability 62.9%)
2.85 L/h
Central volume of distribution
15.4 L
Peripheral volume of distribution
12.3 L
Inter-compartmental distribution clearance
2.1 L/h
Observational data: associations, not effects.
Original publication
Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: Does inflammation play a role? J Crit Care. Published 3 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →